Cardinal Health (CAH) Tops Q1 EPS by 28c

Go back to Cardinal Health (CAH) Tops Q1 EPS by 28c

Leerink Partners Raises Price Target on Cardinal Health (CAH) Following Conference Call

November 4, 2015 3:03 PM EST

Leerink Partners reiterated an Outperform rating on Cardinal Health (NYSE: CAH), and raised the price target to $105.00 (from $100.00), following the company's 1Q16 earnings conference call. The strong 49bp increase in pharmaceutical segment operating margin (to 2.61%) was driven by generic strength. F2016 pharmaceutical segment revenue is now expected to be in the... More

UBS Raises Price target on Cardinal Health (CAH) Following 1Q16 Conference Call

November 3, 2015 8:36 AM EST

UBS reiterated a Buy rating on Cardinal Health (NYSE: CAH), and raise the price target to $100.00 (from $97.00), following 1Q16 earnings call. On CAH's F1Q16 earnings call, the company provided some fresh input on the outlook for both brand and generic pricing. Regarding brand drug inflation, the rate in F1Q16 was slightly higher than the prior... More